The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy

References

• Akerblad, A.C., Bengtsson, F., Holgersson, M., von Knorring, L. & Ekselius, L. (2008). Identification of primary care patients at risk of nonadherence to antidepressant treatment. Patient Preference and Adherence, 2, 379–386.
   PubMedGoogle Scholar
• Alexopoulos, G. S. (2005). Depression in the elderly. Lancet, 365, 1961–1970.
   PubMed Web of Science ®Google Scholar
• Altar, C.A. (2008). The Biomarkers Consortium: On the critical path of drug discovery. Clinical Pharmacology and Therapeutics, 83, 361–364.
   PubMedGoogle Scholar
• Baumann, P. (1996). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 31, 444–469.
   PubMed Web of Science ®Google Scholar
• Bengtsson, F. (2004). Therapeutic drug monitoring of psychotropic drugs. TDM ‘nouveau’. Therapeutic Drug Monitoring, 26, 145–151.
   PubMed Web of Science ®Google Scholar
• Blackwell, B., Stefopoulos, A., Enders, P., Kuzma, R., & Adolphe, A. (1978). Anticholinergic activity of two tricyclic antidepressants. Am J Psychiatry, 135, 722–724.
   PubMed Web of Science ®Google Scholar
• Bressler, R., Bahl, J. J. (2003). Principles of drug therapy for the elderly patient. Mayo Clin Proc, 78, 1564–1577.
   PubMed Web of Science ®Google Scholar
• Buchtemann, D., Luppa, M., Bramesfeld, A., & Riedel-Heller, S. (2012). Incidence of late-life depression: a systematic review. J Affect Disord, 142, 172–179.
   PubMed Web of Science ®Google Scholar
• Caccia, S. & Garattini, S. (1992). Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacological Research, 26, 317–329.
   PubMed Web of Science ®Google Scholar
• Cancelli, I., Beltrame, M., D’Anna, L., Gigli, G.L. & Valente, M. (2009). Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease? Expert Opinion on Drug Safety, 8, 549–557.
   PubMed Web of Science ®Google Scholar
• Carnahan, R.M., Lund, B.C., Perry, P.J., Pollock, B.G. & Culp, K.R. (2006). The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. Journal of Clinical Pharmacology, 46, 1481–1486.
   PubMed Web of Science ®Google Scholar
• Catafau, A.M., Perez, V., Plaza, P., Pascual, J.C., Bullich, S., Suarez, M., … Alvarez, E. (2006). Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: A 123I-ADAM SPECT study. Psychopharmacology, 189, 145–153.
   PubMed Web of Science ®Google Scholar
• Chen, K.P., Shen, W.W. & Lu, M.L. (2004). Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry and Clinical Neurosciences, 58, 25–29.
   PubMed Web of Science ®Google Scholar
• Chew, M.L., Mulsant, B.H., Pollock, B.G., Lehman, M.E., Greenspan, A., Mahmoud, R.A., … Gharabawi, G. (2008). Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society, 56, 1333–1341.
   PubMed Web of Science ®Google Scholar
• Christensen, P., Thomsen, H.Y., Pedersen, O.L., Thayssen, P., Oxhoj, H., Kragh-Sorensen, P. & Gram, L.F. (1985). Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients. Psychopharmacology, 87, 212–215.
   PubMed Web of Science ®Google Scholar
• Collins, N., Barnes, T.R., Shingleton-Smith, A., Gerrett, D. & Paton, C. (2010). Standards of lithium monitoring in mental health ttrusts in the UK. BMC Psychiatry, 10, 80.
   PubMedGoogle Scholar
• Conney, J. & Kaston, B. (1999). Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: Influence of drug-related morbidity on total cost of treatment. American Journal of Managed Care, 5, 197–204.
   PubMedGoogle Scholar
• Coppen, A., Abou-Saleh, M., Milln, P., Bailey, J. & Wood, K. (1983). Decreasing lithium dosage reduces morbidity and side-effects during prophylaxis. Journal of Affective Disorders, 5, 353–362.
   PubMed Web of Science ®Google Scholar
• Coppen, A. & Wood, K. (1979). Adrenergic and serotonergic mechanisms in depression and their response to amitriptyline. Ciba Foundation Symposium, 74, 157–166.
   Google Scholar
• Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011). Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 343, d4551.
   Google Scholar
• de Boer, R.A., van Dijk, T.H., Holman, N.D. & van Melle, J.P. (2005). QT interval prolongation after sertraline overdose: A case report. BMC Emergency Medicine, 5, 5.
   PubMedGoogle Scholar
• de Leon, J., Armstrong, S. C., & Cozza, K. L. (2005). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–273.
   PubMed Web of Science ®Google Scholar
• de Leon, J. (2009). The future (or lack of future) of personalized prescription in psychiatry. Pharmacological Research, 59, 81–89.
   PubMed Web of Science ®Google Scholar
• Degner, D., Grohmann, R., Kropp, S., Ruther, E., Bender, S., Engel, R.R. & Schmidt, L.G. (2004). Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry, 37 (Suppl. 1), S39–45.
   PubMedGoogle Scholar
• Demyttenaere, K., Enzlin, P., Dewe, W., Boulanger, B., De Bie, J., De Troyer, W. & Mesters, P. (2001). Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. Journal of Clinical Psychiatry, 62 (Suppl. 22), S30–33.
   PubMed Web of Science ®Google Scholar
• Diaz, F.J., de Leon, J., Josiassen, R.C., Cooper, T.B. & Simpson, G.M. (2005). Plasma clozapine concentration coefficients of variation in a long-term study. Schizophrenia Research, 72(2–3), 131–135.
   Google Scholar
• Eagles, J.M., McCann, I., MacLeod, T.N. & Paterson, N. (2000). Lithium monitoring before and after the distribution of clinical practice guidelines. Acta Psychiatrica Scandinavica, 101, 349–353.
   PubMed Web of Science ®Google Scholar
• Frank, E., Perel, J.M., Mallinger, A.G., Thase, M.E. & Kupfer, D.J. (1992). Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacology Bulletin, 28, 231–235.
   PubMedGoogle Scholar
• Fulton, M.M. & Allen, E.R. (2005). Polypharmacy in the elderly: A literature review. Journal of the American Academy of Nurse Practitioners, 17, 123–132.
   PubMedGoogle Scholar
• Fuxe, K., Ogren, S.O., Agnati, L., Gustafsson, J.A. & Jonsson, G. (1977). On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neuroscience Letters, 6, 339–343.
   PubMed Web of Science ®Google Scholar
• Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., … Hamilton, S.P. (2010a). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry, 67, 133–138.
   PubMed Web of Science ®Google Scholar
• Garriock, H.A., Tanowitz, M., Kraft, J.B., Dang, V.C., Peters, E.J., Jenkins, G.D., … Hamilton, S.P. (2010b). Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. American Journal of Psychiatry, 167, 565–573.
   PubMed Web of Science ®Google Scholar
• Gelenberg, A.J. & Jefferson, J.W. (1995). Lithium tremor. Journal of Clinical Psychiatry, 56, 283–287.
   PubMed Web of Science ®Google Scholar
• Gelenberg, A.J., Kane, J.M., Keller, M.B., Lavori, P., Rosenbaum, J.F., Cole, K. & Lavelle, J. (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine, 321, 1489–1493.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry, M., Gervasoni, N., Eap, C.B., Aubry, J.M., Bondolfi, G. & Bertschy, G. (2007). Time course of response to paroxetine: influence of plasma level. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 892–900.
   PubMedGoogle Scholar
• Ghose, K. & Coppen, A. (1977). Noradrenaline, depressive illness, and the action of amitriptyline. Psychopharmacology, 54, 57–60.
   PubMedGoogle Scholar
• Gitlin, M.J., Cochran, S.D. & Jamison, K.R. (1989). Maintenance lithium treatment: Side effects and compliance. Journal of Clinical Psychiatry, 50, 127–131.
   PubMed Web of Science ®Google Scholar
• Glassman, A.H., Rodriguez, A.I. & Shapiro, P.A. (1998). The use of antidepressant drugs in patients with heart disease. Journal of Clinical Psychiatry, 59(Suppl. 10), 16–21.
   PubMedGoogle Scholar
• Glotzbach, R.K. & Preskorn, S.H. (1982). Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology, 78, 25–27.
   Google Scholar
• Gopinath, S., Katon, W.J., Russo, J.E. & Ludman, E.J. (2007). Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. Journal of Affective Disorders, 101, 57–63.
   PubMedGoogle Scholar
• Grandjean, E.M. & Aubry, J.M. (2009). Lithium: Updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs, 23, 331–349.
   PubMed Web of Science ®Google Scholar
• Grozinger, M., Dragicevic, A., Hiemke, C., Shams, M., Muller, M.J. & Hartter, S. (2003). Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry, 36, 3–6.
   PubMedGoogle Scholar
• Grozinger, M., Hartter, S., Hiemke, C. & Roschke, J. (1999). Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. Journal of Clinical Psychopharmacology, 19, 287–289.
   PubMedGoogle Scholar
• Grunder, G., Hiemke, C., Paulzen, M., Veselinovic, T. & Vernaleken, I. (2011). Therapeutic plasma concentrations of antidepressants and antipsychotics: Lessons from PET imaging. Pharmacopsychiatry, 44(6), 236–248.
   Google Scholar
• Gupta, N. (2001). Guidelines for lithium monitoring: Are they ideal? Acta Psychiatrica Scandinavica, 104(1), 76–77.
   Google Scholar
• Gupta, S.K., Shah, J.C. & Hwang, S.S. (1999). Pharmacokinetic and pharmacodynamic characterization of OROS(R) and immediate-release amitriptyline. British Journal of Clinical Pharmacology, 48, 71–78.
   PubMedGoogle Scholar
• Haen, E., Greiner, C., Bader, W. & Wittmann, M. (2008). Wirkstoffkonzentrationsbestimmungen zur Therapieleitung[Expanding therapeutic reference ranges using dose-related reference ranges]. Der Nervenarzt, 79, 558–566.
   PubMedGoogle Scholar
• Hardy, B.G., Shulman, K.I., Mackenzie, S.E., Kutcher, S.P. & Silverberg, J.D. (1987). Pharmacokinetics of lithium in the elderly. Journal of Clinical Psychopharmacology, 7, 153–158.
   PubMedGoogle Scholar
• Hendset, M., Haslemo, T., Rudberg, I., Refsum, H. & Molden, E. (2006). The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry, 39, 121–127.
   PubMedGoogle Scholar
• Hiemke, C. (2008). Therapeutic drug monitoring in neuropsychopharmacology: Does it hold its promises? European Archives of Psychiatry and Clinical nNeuroscience, 258 (Suppl. 1), 21–27.
   PubMedGoogle Scholar
• Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., … Zernig, G. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry, 44, 195–235.
   Web of Science ®Google Scholar
• Hiemke, C. & Hartter, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics, 85, 11–28.
   PubMed Web of Science ®Google Scholar
• Hilmer, S.N., McLachlan, A.J. & Couteur, D.G.L. (2007). Clinical pharmacology in the geriatric patient. Fundamental and Clinical Pharmacology, 21, 217–230.
   PubMed Web of Science ®Google Scholar
• Holt, S., Schmiedl, S. & Thürmann, P.A. (2010). Potentially inappropriate medications in the elderly: The PRISCUS list. Deutsches Ärzteblatt International, 107, 543–551.
   PubMed Web of Science ®Google Scholar
• Hsu, C.H., Liu, P.Y., Chen, J.H., Yeh, T.L., Tsai, H.Y. & Lin, L.J. (2005). Electrocardiographic abnormalities as predictors for over-range lithium levels. Cardiology, 103, 101–106.
   PubMed Web of Science ®Google Scholar
• Isbister, G.K., Bowe, S.J., Dawson, A. & Whyte, I.M. (2004). Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of Toxicology. Clinical Toxicology, 42, 277–285.
   PubMed Web of Science ®Google Scholar
• Jeste, D.V., Alexopoulos, G.S., Bartels, S.J., Cummings, J.L., Gallo, J.J., Gottlieb, G.L., … Lebowitz, B.D. (1999). Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next 2 decades. Archives of General Psychiatry, 56, 848–853.
   PubMed Web of Science ®Google Scholar
• Khalifa, E., Toner, J.P., Muasher, S.J. & Acosta, A.A. (1992). Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization. Fertility and Sterility, 57, 835–839.
   PubMedGoogle Scholar
• Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L., Licinio, J., Roots, I. & Brockmoller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9, 442–473.
   PubMed Web of Science ®Google Scholar
• Krishnan, K.R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., … Wainscott, C. (2002). Comorbidity of depression with other medical diseases in the elderly. Biological Psychiatry, 52, 559–588.
   PubMed Web of Science ®Google Scholar
• Kurz, M., Hummer, M., Kemmler, G., Kurzthaler, I., Saria, A. & Fleischhacker, W.W. (1998). Long-term pharmacokinetics of clozapine. British Journal of Psychiatry, 173, 341–344.
   PubMed Web of Science ®Google Scholar
• Lapid, M.I. & Rummans, T.A. (2003). Evaluation and management of geriatric depression in primary care. Mayo Clinic Proceedings, 78, 1423–1429.
   PubMed Web of Science ®Google Scholar
• Low, P.A. & Opfer-Gehrking, T.L. (1992). Differential effects of amitriptyline on sudomotor, cardiovagal, and adrenergic function in human subjects. Muscle and Nerve, 15, 1340–1344.
   PubMedGoogle Scholar
• Lundmark, J., Bengtsson, F., Nordin, C., Reis, M. & Walinder, J. (2000a). Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatrica Scandinavica, 101, 354–359.
   PubMed Web of Science ®Google Scholar
• Lundmark, J., Reis, M. & Bengtsson, F. (2000b). Therapeutic drug monitoring of sertraline: Variability factors as displayed in a clinical setting. Therapeutic Drug Monitoring, 22, 446–454.
   PubMed Web of Science ®Google Scholar
• Luukkanen, M.J., Uusvaara, J., Laurila, J.V., Strandberg, T.E., Raivio, M.M., Tilvis, R.S. & Pitkala, K.H. (2011). Anticholinergic drugs and their effects on delirium and mortality in the elderly. Dementia and Geriatric Cognitive Disorders Extra, 1, 43–50.
   PubMedGoogle Scholar
• Mallet, L., Spinewine, A. & Huang, A. (2007). The challenge of managing drug interactions in elderly people. Lancet, 370, 185–191.
   PubMed Web of Science ®Google Scholar
• Mangoni, A.A., & Jackson, S.H. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol, 57, 6–14.
   PubMed Web of Science ®Google Scholar
• McLean, A.J., & Le Couteur, D.G. (2004). Aging biology and geriatric clinical pharmacology. Pharmacol Rev, 56, 163–184.
   PubMed Web of Science ®Google Scholar
• Melfi, C.A., Chawla, A.J., Croghan, T.W., Hanna, M.P., Kennedy, S. & Sredl, K. (1998). The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry, 55, 1128–1132.
   PubMed Web of Science ®Google Scholar
• Meyer, J.H., Wilson, A.A., Sagrati, S., Hussey, D., Carella, A., Potter, W.Z., … Houle, S. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. American Journal of Psychiatry, 161, 826–835.
   PubMed Web of Science ®Google Scholar
• Mintzer, J. & Burns, A. (2000). Anticholinergic side-effects of drugs in elderly people. Journal of the Royal Society of Medicine, 93, 457–462.
   PubMed Web of Science ®Google Scholar
• Muller, M.J., Dragicevic, A., Fric, M., Gaertner, I., Grasmader, K., Hartter, S., … Hiemke, C. (2003). Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions? Pharmacopsychiatry, 36, 98–104.
   PubMed Web of Science ®Google Scholar
• Olfson, M., Marcus, S.C., Tedeschi, M. & Wan, G.J. (2006). Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry, 163, 101–108.
   PubMed Web of Science ®Google Scholar
• Ostad Haji, E., Tadic, A., Wagner, S., Dragicevic, A., Muller, M.J., Boland, K., … Hiemke, C. (2011). Association between citalopram serum levels and clinical improvement of patients with major depression. Journal of Clinical Psychopharmacology, 31, 281–286.
   PubMed Web of Science ®Google Scholar
• Pacher, P. & Kecskemeti, V. (2004). Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Current Pharmaceutical Design, 10, 2463–2475.
   PubMed Web of Science ®Google Scholar
• Parsey, R.V., Kent, J.M., Oquendo, M.A., Richards, M.C., Pratap, M., Cooper, T.B., … Mann, J.J. (2006). Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biological Psychiatry, 59, 821–828.
   PubMed Web of Science ®Google Scholar
• Pascual, J. & Woodhouse, K. (1994). Pharmacological treatment of benign prostatic hyperplasia. British Journal of Clinical Practice, 48, 137–138.
   PubMedGoogle Scholar
• Pedersen, O.L., Gram, L.F., Kristensen, C.B., Moller, M., Thayssen, P., Bjerre, M., … Brinklo, M. (1982). Overdosage of antidepressants: clinical and pharmacokinetic aspects. European Journal of Clinical Pharmacology, 23, 513–521.
   PubMedGoogle Scholar
• Perel, J.M. (1988). Compliance during tricyclic antidepressant therapy: Pharmacokinetic and analytical issues. Clinical Chemistry, 34, 881–887.
   PubMedGoogle Scholar
• Perry, P.J., Zeilmann, C. & Arndt, S. (1994). Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. Journal of Clinical Psychopharmacology, 14, 230–240.
   PubMed Web of Science ®Google Scholar
• Pfuhlmann, B., Gerlach, M., Burger, R., Gonska, S., Unterecker, S., Jabs, B., … Deckert, J. (2007). Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. Journal of Neural Transmission. Supplementum, 72, 287–296.
   PubMedGoogle Scholar
• Preskorn, S.H. (1986). Tricyclic antidepressant plasma level monitoring: An improvement over the dose–response approach. Journal of Clinical Psychiatry, 47 (Suppl. 1), S24–30.
   PubMedGoogle Scholar
• Preskorn, S.H. & Fast, G.A. (1991). Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry, 52(Suppl.), 23–33.
   PubMedGoogle Scholar
• Preskorn, S.H. & Fast, G.A. (1992). Tricyclic antidepressant-induced seizures and plasma drug concentration. Journal of Clinical Psychiatry, 53, 160–162.
   PubMed Web of Science ®Google Scholar
• Preskorn, S.H. & Jerkovich, G.S. (1990). Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors, and role of therapeutic drug monitoring. Journal of Clinical Psychopharmacology, 10, 88–95.
   PubMed Web of Science ®Google Scholar
• Preskorn, S.H. & Simpson, S. (1982). Tricyclic-antidepressant-induced delirium and plasma drug concentration. American Journal of Psychiatry, 139, 822–823.
   PubMed Web of Science ®Google Scholar
• Rechlin, T., Claus, D., Weis, M. & Kaschka, W. (1995). Decreased heart rate variability parameters in amitriptyline treated depressed patients: Biological and clinical significance. European Psychiatry, 10, 189–194.
   PubMedGoogle Scholar
• Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., … Hammond, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.
   PubMed Web of Science ®Google Scholar
• Reis, M., Aberg-Wistedt, A., Agren, H., Akerblad, A.C. & Bengtsson, F. (2004). Compliance with SSRI medication during 6 months of treatment for major depression: An evaluation by determination of repeated serum drug concentrations. Journal of Affective Disorders, 82, 443–446.
   PubMedGoogle Scholar
• Reis, M., Cherma, M.D., Carlsson, B. & Bengtsson, F. (2007). Therapeutic drug monitoring of escitalopram in an outpatient setting. Therapeutic Drug Monitoring, 29, 758–766.
   PubMed Web of Science ®Google Scholar
• Reis, M., Lundmark, J., Bjork, H. & Bengtsson, F. (2002). Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Therapeutic Drug Monitoring, 24, 545–553.
   PubMed Web of Science ®Google Scholar
• Reis, M., Prochazka, J., Sitsen, A., Ahlner, J. & Bengtsson, F. (2005). Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: A 6-month therapeutic drug monitoring study. Therapeutic Drug Monitoring, 27, 469–477.
   PubMed Web of Science ®Google Scholar
• Roden, D.M. (2004). Drug therapy: Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350, 1013–1022.
   PubMed Web of Science ®Google Scholar
• Rodriguez de la Torre, B., Dreher, J., Malevany, I., Bagli, M., Kolbinger, M., Omran, H., … Rao, M.L. (2001). Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Therapeutic Drug Monitoring, 23, 435–440.
   PubMed Web of Science ®Google Scholar
• Sharma, S., Joshi, S. & Chadda, R.K. (2009). Therapeutic drug monitoring of lithium in patients with bipolar affective disorder: Experiences from a tertiary care hospital in India. American Journal of Therapeutics, 16, 393–397.
   PubMedGoogle Scholar
• Skogh, E., Reis, M., Dahl, M.L., Lundmark, J. & Bengtsson, F. (2002). Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Therapeutic Drug Monitoring, 24, 518–526.
   PubMed Web of Science ®Google Scholar
• Soares, J.C., Boada, F., Spencer, S., Mallinger, A.G., Dippold, C.S., Wells, K.F., … Kupfer, D.J. (2001). Brain lithium concentrations in bipolar disorder patients: Preliminary (7)Li magnetic resonance studies at 3 T. Biological Psychiatry, 49, 437–443.
   PubMedGoogle Scholar
• Stieffenhofer, V. & Hiemke, C. (2010). Pharmakogenetik, Therapeutisches Drug Monitoring und Noncompliance [Pharmacogenetics, therapeutic drug monitoring and non compliance]. Therapeutische Umschau. Revue Therapeutique, 67, 309–315.
   PubMedGoogle Scholar
• Stoudemire, A., Moran, M.G. & Fogel, B.S. (1990). Psychotropic drug use in the medically ill: Part I. Psychosomatics, 31, 377–391.
   PubMedGoogle Scholar
• Suhara, T., Takano, A., Sudo, Y., Ichimiya, T., Inoue, M., Yasuno, F., … Okubo, Y. (2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Archives of General Psychiatry, 60, 386–391.
   PubMed Web of Science ®Google Scholar
• Swift, C.G., Haythorne, J.M., Clarke, P. & Stevenson, I.H. (1981). Cardiovascular, sedative and anticholinergic effects of amitriptyline and zimelidine in young and elderly volunteers. Acta Psychiatrica Scandinavica Supplementum, 290, 425–432.
   PubMedGoogle Scholar
• Takano, A., Halldin, C. & Farde, L. (2013). SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study. Psychopharmacology, 226, 147–153.
   PubMed Web of Science ®Google Scholar
• Takano, A., Suhara, T., Ichimiya, T., Yasuno, F. & Suzuki, K. (2006). Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. Journal of Clinical Psychopharmacology, 26, 188–191.
   PubMed Web of Science ®Google Scholar
• Taylor, D. (2008). Antidepressant drugs and cardiovascular pathology: A clinical overview of effectiveness and safety. Acta Psychiatrica Scandinavica, 118, 434–442.
   PubMed Web of Science ®Google Scholar
• Tellian, F.F. & Rueda-Vasquez, E. (1993). Effect of serum lithium levels on thyrotropin levels. Southern Medical Journal, 86, 1182–1183.
   PubMedGoogle Scholar
• Thundiyil, J. G., Kearney, T. E., & Olson, K. R. (2007). Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol, 3, 15–19.
   PubMedGoogle Scholar
• Turnheim, K. (2003). When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Experimental Gerontology, 38, 843–853.
   PubMed Web of Science ®Google Scholar
• Ulrich, S. & Lauter, J. (2002). Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clinical Pharmacokinetics, 41, 853–876.
   PubMed Web of Science ®Google Scholar
• Unterecker, S., Warrings, B., Deckert, J. & Pfuhlmann, B. (2012). Correlation of QTc interval prolongation and serum level of citalopram after intoxication – A case report. Pharmacopsychiatry, 45, 30–34.
   PubMedGoogle Scholar
• Voineskos, A.N., Wilson, A.A., Boovariwala, A., Sagrati, S., Houle, S., Rusjan, P., … Meyer, J.H. (2007). Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology, 193, 539–545.
   PubMed Web of Science ®Google Scholar
• White, N., Litovitz, T. & Clancy, C. (2008). Suicidal antidepressant overdoses: A comparative analysis by antidepressant type. Journal of Medical Toxicology, 4, 238–250.
   PubMedGoogle Scholar
• Wilting, I., Heerdink, E.R., Mersch, P.P., den Boer, J.A., Egberts, A.C. & Nolen, W.A. (2009). Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: A naturalistic follow-up study. Bipolar Disorders, 11, 434–440.
   PubMedGoogle Scholar